Friday, July 20, 2018
 
 
Company News: Page (1) of 1 - 07/05/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Global Hemophilia Treatment Drugs Market Will Reach USD 25.61 Billion by 2024: Zion Market Research

(July 05, 2018)

According to the report, global hemophilia treatment drugs market was valued at approximately USD 17.37 billion in 2017 and is expected to generate revenue of around USD 25.61 billion by the end of 2024, growing at a CAGR of around 5.7% between 2017 and 2024.

New York, NY, July 05, 2018 (GLOBE NEWSWIRE) -- Zion Market Research has published a new report titled “Hemophilia Treatment Drugs Market by Product Type (Recombinant Coagulation Factor Concentrates, Plasma Derived Coagulation Factor Concentrates, Desmopressin, and Antifibrinolytic Agents), by Disease Type (Hemophilia A, Hemophilia B, and Others), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and E-Commerce) - Global Industry Perspective, Comprehensive Analysis and Forecast, 2017 - 2024”. According to the report, global hemophilia treatment drugs market was valued at approximately USD 17.37 billion in 2017 and is expected to generate revenue of around USD 25.61 billion by the end of 2024, growing at a CAGR of around 5.7% between 2017 and 2024.

Hemophilia is a genetic disorder in which the blood clotting factors are reduced; this hampers the function of blood clotting and leads to abnormal internal and external bleeding after any type of injuries. Hemophilia A and hemophilia B are the main types of hemophilia which are commonly seen in patients. Hemophilia A occurs when clotting factor VIII is reduced whereas hemophilia B occurs when clotting factor IX is reduced. Hemophilia C and parahemophilia are rare types of hemophilia which occur when there is a reduction in clotting factor XI and clotting factor V respectively.

Browse through 54 Tables & 26 Figures spread over 110 Pages and in-depth TOC on "Global Hemophilia Treatment Drugs Market Size, Share, Industry Developments, Applications, and Forecast, 2017 - 2024”.



Request Free Sample Report of Global Hemophilia Treatment Drugs Market Report @ https://www.zionmarketresearch.com/sample/hemophilia-treatment-drugs-market

The global hemophilia treatment drugs market is segregated on the basis of product type, disease type, and distribution channel. The product type segment is divided into RCFC, PDCFC, desmopressin, and antifibrinolytic agent. The RCFC segment is anticipated to dominate the hemophilia treatment drugs market. The preference for recombinant factor concentrates has increased as it has a low risk of infections thus fuelling the growth of this segment. The PDCFC is also expected to show a significant growth. Plasma derivatives are fractions that are isolated from human blood which contains three main components namely immunoglobin, albumin, and clotting factors. In countries such as China and Japan, there is an increase in demand for this concentrates which is expected to fuel the growth of this segment.

The disease type segment includes hemophilia B, hemophilia A, and others. In 2016, there were approximately 149,800 patients suffering from hemophilia A. Due to the increase in the number of patients of hemophilia A, this segment is expected to lead the disease type segment. Based on distribution channel, the market is further segmented into hospital pharmacies, retail pharmacies, and e-commerce. The hospital pharmacies segment is anticipated to lead the global hemophilia treatment drugs market.

Download Free Report Brochure @ https://www.zionmarketresearch.com/requestbrochure/hemophilia-treatment-drugs-market

North America is anticipated to lead the global hemophilia treatment drugs market within the forecast period. In North America, about 80% of the hemophilia patients suffer from severe hemophilia. CDC estimated that in the United States 1 in every 5000 newborn children suffers from hemophilia A and 1 in every 30,000 suffers from hemophilia B. Growing prevalence of hemophilia disease, increasing usage of the recombinant product, and technological advancements are some of the factors which fuel the growth of hemophilia treatment drugs market in North America. Rising investments in research and development for hemophilia treatment drugs is also expected to fuel the growth of the market.

Europe is the second largest market and is expected to grow at a significant rate within the forecast period. Europe hemophilia treatment drugs market is driven by factors such as growing prevalence of hemophilia A, increasing government support, and increasing usage of recombinant products. Technological advancements along with rising investments in research and innovation of new hemophilia products are also some of the key factors fuelling the growth of the market.

Browse the full "Hemophilia Treatment Drugs Market by Product Type (Recombinant Coagulation Factor Concentrates, Plasma Derived Coagulation Factor Concentrates, Desmopressin, and Antifibrinolytic Agents), by Disease Type (Hemophilia A, Hemophilia B, and Others), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and E-Commerce) - Global Industry Perspective, Comprehensive Analysis and Forecast, 2017 - 2024" report at https://www.zionmarketresearch.com/report/hemophilia-treatment-drugs-market

The Asia Pacific is expected to show higher growth rates over the forecast period in the global hemophilia treatment drugs market, with China and India being the fastest-growing markets in the Asia Pacific region. A large pool of patients, heightened awareness regarding overall healthcare, increasing medical tourism, improving healthcare infrastructure, and augmented healthcare expenditure in the Asia Pacific are the key driving forces for the hemophilia treatment drugs market. The attraction of various industries for the introduction of their products in countries like China and Japan has also driven the growth of the market in this region.

The Middle East and Africa and Latin America are expected to witness a rapid growth within the forecast period. The growth of e-commerce has helped in increasing awareness about the treatment of hemophilia. This spurs the growth of the market in these regions. Also, increase in the number of hemophilia patients drives the market in this region.

Inquire more about this report before purchase @ https://www.zionmarketresearch.com/inquiry/hemophilia-treatment-drugs-market

Some of the key players in the global hemophilia treatment drugs market are Shire Plc., Novo Nordisk A/S, Pfizer, Bayer AG, CSL Ltd., Biogen, and others. Major players are frequently engaged in the development of new drugs for the treatment of hemophilia.

Request customized copy of report @ https://www.zionmarketresearch.com/custom/3187

This report segments the global hemophilia treatment drugs market as follows:

Global Hemophilia Treatment Drugs Market: Product Type Segment Analysis

  • Recombinant Coagulation Factor Concentrates
  • Plasma Derived Coagulation Factor Concentrates
  • Desmopressin
  • Antifibrinolytic Agents

Global Hemophilia Treatment Drugs Market: Disease Type Segment Analysis

  • Hemophilia A
  • Hemophilia B
  • Others

Global Hemophilia Treatment Drugs Market: Distribution Channel Segment Analysis

  • Hospital Pharmacies
  • Retail Pharmacies
  • E-Commerce

Global Hemophilia Treatment Drugs Market: Regional Segment Analysis

  • North America
    • The U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • The Middle East and Africa

Related Reports:

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Follow Us LinkedIn: https://www.linkedin.com/company/zion-market-research
Follow Us Twitter: https://twitter.com/zion_research

Blog: http://www.intenseresearch.com | http://www.mrsresearchgroup.com | http://www.marketresearchtrade.com | https://qyresearchgroup.com | http://marketnreports.com | https://zmrnewsjournal.us | http://www.e-marketresearch.com

Contact Us:

Joel John
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: [email protected]

Website: https://www.zionmarketresearch.com

Blog: http://zmrblog.com


Page: 1


Related Keywords:
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • Healthcare IT Market 2018 - 2023 with SWOT Analysis regarding upcoming Changes and Technology Adaptations in Global Healthcare Sector
  • Vision Care Product Market To Witness Enhanced Growth Owing To Rising Occurrence Of Eye Disorders Till 2021 | Million Insights
  • Global Prosthetic Heart Valve Market Reaching at a CAGR of +12.70% by Geography, Deployment Model, Component, and Key players are Boston Scientific Cardiology, CryoLife, Inc., Abbott
  • Trauma Fixation Global Market to Register Steady Expansion During 2018-2025
  • Global Surgical Apparel Market Will Reach USD 2,966.58 million by 2024: Zion Market Research

    Cancer
  • Mesothelioma is a Deadly Cancer and it’s Completely Preventable
  • HedgePath Pharmaceuticals Granted Exclusive Option to License UCONN's Patented Chemical Analogues of Itraconazole
  • Alligator Bioscience Submits Application to Start Clinical Phase I Study in Cancer Patients with ATOR-1015, a Unique CTLA-4 and OX40 Binding Antibody
  • Yisheng Biopharma Announces Opening of New Business Divisions in Cambodia, Expanding Presence within Southeast Asia
  • Omega-3 Market to Reach US$ 16.37 Bn by 2023, Globally - QYResearch.com
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines